This study is in progress, not accepting new patients

Effects of GRA in Patients With Type 1

a study on Diabetes Diabetes Type 1 Insulin Resistance

Summary

Eligibility
for people ages 18-65 (full criteria)
Location
at La Jolla, California
Dates
study started
completion around
Principal Investigator
by Jeremy Pettus, MD
Headshot of Jeremy Pettus
Jeremy Pettus

Description

Summary

This study will examine the effects a Glucagon Receptor Antagonist (GRA), has on Insulin Sensitivity, Cardiovascular risks (CVD), and Ketone body formation in participants with Type 1 diabetes. The participants will complete blood tests, tests to measure energy expenditure, CVD risks, and insulin resistance. These tests will be performed prior to start of treatment and again after 12-weeks of treatment with the GRA (called REMD-477).

Official Title

The Effects of Glucagon Antagonism on Insulin Sensitivity, Cardiovascular Risk, and Ketogenesis in Type 1 Diabetes

Details

This single-center, double-blind, placebo-controlled, multi-dose study is designed to evaluate the effects of glucagon antagonism on insulin sensitivity, cardiovascular risk and ketogenesis in individuals with Type 1 Diabetes. To accomplish the specific aims proposed, a single clinical trial will be conducted in which a maximum of 30 subjects with T1D, who are otherwise healthy, will be treated with REMD-477 or matching placebo for up to 12 weeks at a dose of 70mg (administered subcutaneously each week) with assessments done pre- and post-therapy. Subjects will be randomized on a 1:1 basis to either the REMD-477 group or placebo group and all subjects will remain on their standard of care insulin therapy throughout the study. There will be 19 study visits as outlined below:

  1. Screening - Complete consenting process, complete medical history and physical exam, review of current medications, collect height/weight, vital signs, and fasting laboratory (blood and urine) tests.
  2. Baseline Visit 1 - Participants that meet screening criteria will complete cardiovascular tests including flow mediated dilation and EndoPat, complete vital signs, weight and laboratory tests for safety and CVD markers.
  3. Baseline Visit 2 - Participants will complete a 2-Step Hyperinsulinemic/Euglycemic clamp with tracer, Indirect Calorimetry, muscle and adipose tissue biopsies.
  4. Baseline Visit 3 - Insulin withdrawal challenge and injection #1 of REMD-477 or placebo. Participants will suspend insulin delivery and remove insulin pump. Blood sugars and ketones will be monitored for up to 8 hours.
  5. Visit 4 - Injection #2 of REMD-477 or placebo and blood collection for safety labs.
  6. Visit 5 - Injection #3 of REMD-477 or placebo.
  7. Visit 6 - Injection #4 of REMD-477 or placebo and blood collection for safety labs.
  8. Visit 7 - Injection #5 of REMD-477 or placebo.
  9. Visit 8 - Injection #6 of REMD-477 or placebo and blood collection for safety labs.
  10. Visit 9 - Injection #7 of REMD-477 or placebo.
  11. Visit 10 - Injection #8 of REMD-477 or placebo and blood collection for safety labs.
  12. Visit 11 - Injection #9 of REMD-477 or placebo.
  13. Visit 12 - Injection #10 of REMD-477 or placebo and blood collection for safety labs.
  14. Visit 13 - Injection #11 of REMD-477 or placebo.
  15. Visit 14 - Injection #12 of REMD-477 or placebo and blood collection for safety labs.
  16. Visit 15 - Repeat cardiovascular tests including flow mediated dilation and EndoPat, complete vital signs, weight and laboratory tests for safety and CVD markers.
  17. Visit 16 - Repeat 2-Step Hyperinsulinemic/Euglycemic clamp with tracer, Indirect Calorimetry, muscle and adipose tissue biopsies.
  18. Visit 17 - Repeat Insulin withdrawal challenge. Participants will suspend insulin delivery and remove insulin pump. Blood sugars and ketones will be monitored for up to 8 hours.
  19. Visit 18 - Safety follow-up visit that includes physical exam, vitals, blood and urine sample collection.

Keywords

Type 1 Diabetes, Type 1 Diabetes Mellitus, Volagidemab, REMD-477

Eligibility

You can join if…

Open to people ages 18-65

  1. Men and women between the ages of 18 and 65 years old, inclusive, at the time of screening;
  2. Females of non-child bearing potential must be ≥ 1 year post-menopausal or documented as being surgically sterile. Females of child bearing potential must agree to use two methods of contraception during the entire study and for an additional 3 months after the end of dosing with the investigational product;
  3. Male subjects must be willing to use clinically acceptable method of contraception during the entire study and for an additional 6 months after the end of the treatment period;
  4. Diagnosed with Type 1 diabetes based on clinical history or as defined by the current American Diabetes Association (ADA) criteria for > 5 years;
  5. Treatment with a stable insulin regimen for at least 8 weeks before screening with continuous subcutaneous insulin infusion (CSII) via an insulin pump;
  6. Currently using a Continuous Glucose Monitoring (CGM) system;
  7. HbA1c ≤ 8.5 % at screening;
  8. A minimum weight of 50kg;
  9. eGFR ≥ 60 mL/min/1.73m²
  10. Able to provide written informed consent approved by an Institutional Review Board (IRB).

You CAN'T join if...

  1. History or evidence of clinically-significant disorder or condition that, in the opinion of the Investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion;
  2. History of pancreatitis, medullary thyroid carcinoma and/or liver disease;
  3. Clinically significant diagnosis of anemia;
  4. Body Mass Index (BMI) < 18.5 kg/m2 and/or weight less than 50kg;
  5. Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening. Donations of plasma, packed RBCs, platelets or quantities less than 500 mL are allowed at investigator discretion;
  6. Current or recent (within 1 month of screening) use of diabetes medications other than insulin;
  7. Women who are pregnant or lactating/breastfeeding;
  8. Unable or unwilling to follow the study protocol or who are non-compliant with screening appointments or study visits;
  9. Any other condition(s) that might reduce the chance of obtaining study data, or that might cause safety concerns, or that might compromise the ability to give truly informed consent.

Location

  • UC San Diego Altman Clinical & Translational Research Institute
    La Jolla California 92037 United States

Lead Scientist at UCSD

  • Jeremy Pettus, MD
    Associate Professor, Medicine, Vc-health Sciences-schools. Authored (or co-authored) 74 research publications

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Diego
ID
NCT04779645
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 30 people participating
Last Updated